Can differences in T1 Relaxivity between Gadolinium-based contrast agents be taken advantage of to lower the administered dose of gadolinium? - a podcast by AJR

Full article: https://www.ajronline.org/doi/abs/10.2214/AJR.21.25924 

Intracranial deposition of gadolinium after contrast-enhanced MRI is an emerging area of concern with much still to be learned. Kalen Riley, MD, MBA discusses a new article that proposes a dose-reduction strategy that takes advantage of relatively higher T1 relaxivity of one macrocyclic agent compared to another while still striving to maintain an adequate imaging examination.

Further episodes of AJR Podcast Series

Further podcasts by AJR

Website of AJR